| The Dow led US benchmarks higher on Monday with a 1.3% gain. The S&P 500 added 0.9%, and the Nasdaq gained 0.8%. The small-cap Russell 2K closed with a half-point gain. This morning, futures are in the green. S&P 500 and Dow futures are up 0.3%. Shocking Warning: A "Nightmare Winter" is Coming... ð¨ The Elite Establishment is playing two dangerous games at once⦠They are aiming to change the way a modern economy works, by mandating a complete switch to âgreen energyâ⦠And, they're paying for it with unlimited amounts of new âpaperâ money. This is going to be really bad for a lot of peopleâbut it doesnât have to be bad for you. Making a few simple moves now could spare you from catastrophic losses down the road, but you need to get started right away. Fortunately, two investing legends have teamed up to bring you all the resources you need to make it through in one piece. See Their Full Briefing Here and Take Action Now. Election Day. The midterm elections are today, but it might be some time before all the races are called. However, the stakes are undoubtedly high. Control of both the House and Senate are up for grabs. SolarEdge Technologies Inc [SEDG] - Last Close: $90.79 SolarEdge is moving higher after an earnings release. The solar energy stock posted beat analysts' estimates on its Q3 earnings report. SolarEdge reported adjusted quarterly EPS of $0.91, missing The Street's $1.44 estimate, but revenues of $836.72 million topped the $822.37 million estimate. The company also released an upbeat Q4 revenue view of $855 to $885 million, which outpaced analysts' $856.8 million consensus. SEDG is leading the S&P 500 with a 10.7% gain. My Take: SEDG has been fluctuating between $200 and $350 per share for the trailing 12 months. It's currently resting near the $200 mark. A rally could see some dramatic Neurobo Pharmaceuticals Inc [NRBO] - Last Close: $2.16 Shares of Neurobo Pharma are recovering from Monday's declines. The clinical-stage biotech firm took a 17.2% loss on Monday after announcing a $30 million underwritten public offering and concurrent public placement. However, shares of NRBO are recovering in today's premarket. The stock is heating up on high volume ahead of today's open. NRBO is showing a 38.4% gain, and it's this morning's most actively-traded stock. My Take: Neurobo has a high short ratio of 11.55%, so there could be some elements of a short squeeze in play here. It's possible that Monday's sell-off was overdone, but this stock has been down-trending for months, so I'm not so sure. Ocuphire Pharma Inc [OCUP] - Last Close: $2.08 News of a licensing deal is lifting shares of Ocuphire Pharma. The clinical-stage ophthalmic biopharma firm has entered into a global license agreement for the development and commercialization of its Nyxol eye drops. FamyGen Life Sciences has agreed to develop and commercialize Nyxol following its regulatory approval for three indications in the US, Europe, and Japan. Under the terms of the licensing deal, Ocuphire will receive a $35 million upfront payment, plus Nyxol development funding, potential milestone payments, and tiered double-digit royalties. Ocuphire says the deal will strengthen its financial position, support operations, and fund its APX3330 program into 2025. OCUP is up 19.7%, and it's one of this morning's highest-volume gainers. My Take:Big licensing deal for this micro-cap biotech stock, but it's facing stiff resistance at the $2.75 mark. Pivoting to an up-trend and breaking through its key resistance point could be a challenging task. Hims & Hers Health Inc [HIMS] - Last Close: $4.62 Hims & Hers Health is up big after a blowout earnings report. The multi-specialty telehealth platform posted a double-line beat on its Q3 results. Hims & Hers Health's revenues grew by 95% YoY to $144.8 million, which easily topped analysts' $130.3 million. The company also posted a narrower-than-expected loss of -$(0.09) per share, against the consensus estimate of -$(0.10). Him & Hers' FY2022 revenue view of $519 million to $522 million also surpassed the Street's $479.9 million expectation. HIMS is one of this morning's top performers with a 24.4% gain. My Take:This could be the catalyst HIMS needs to break out of its current slump. The stock almost hit $7.50 per share in August, but it's been down trending ever since. Today's earnings report could be a turning point for the stock. |
